William Blair analyst Brandon Vazquez has maintained their bullish stance on PRCT stock, giving a Buy rating on July 16.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight PROCEPT BioRobotics’ promising future. The appointment of Larry Wood as CEO is a significant development, as Wood brings a wealth of experience from his successful tenure at Edwards Lifesciences, where he played a crucial role in growing the TAVR franchise to multi-billion dollar sales. His leadership is expected to further strengthen PROCEPT’s position and capitalize on growth opportunities.
Additionally, recent positive updates, such as the resolution of reimbursement issues and solid leadership, contribute to the company’s favorable outlook. The company’s attractive valuation, despite recent trading fluctuations, presents a compelling opportunity for investors. These factors collectively underpin Vazquez’s confidence in PROCEPT BioRobotics’ potential, leading to his Buy recommendation.
According to TipRanks, Vazquez is a 2-star analyst with an average return of 1.0% and a 39.39% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, PROCEPT BioRobotics, and Intuitive Surgical.